This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	VEGF receptor 1 (FLT1; VEGFR-1)	<p><i>In vitro</i> and mouse studies suggest increasing monocyte production of soluble FLT1 could enhance the effects of therapeutic antibodies against cancer. In cultured peripheral blood monocytes, stimulation and activation with IgG or therapeutic antibodies increased soluble FLT1 levels compared with no stimulation. In human umbilical vein endothelial cells, supernatant from stimulated monocytes containing soluble FLT1 inhibited angiogenesis compared with supernatant from unstimulated cells. In a mouse model of cancer, a neutralizing antibody targeting soluble FLT1 weakened the anticancer effect of a therapeutic antibody. Next steps could include evaluating the combination of soluble FLT1 and a therapeutic mAb in animal cancer models.</p> <p>SciBX 6(34); doi:10.1038/scibx.2013.924 Published online Sept. 5, 2013</p>	Patent and licensing status unavailable	<p>Justiniano, S.E. <i>et al. J. Biol. Chem.</i>; published online July 31, 2013; doi:10.1074/jbc.M113.485185 Contact: Susheela Tridandapani, The Ohio State University, Columbus, Ohio e-mail: tridandapani.2@osu.edu</p>